The status has been given to the B7-H3-targeted drug as a treatment for late-line relapsed or refractory osteosarcoma, a rare form of bone cancer with no FDA-approved treatments. The coveted ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.